PCVXHIGH SIGNALFINANCIAL10-K

PCVX shows severe financial deterioration with R&D expenses surging 67% to $794M while cash reserves plummeted 55% to $174M, creating potential liquidity concerns.

The company is burning through cash at an accelerated rate with operating cash flow worsening to -$656M, suggesting they may need additional financing within the next 12-18 months. The removal of specific vaccine candidate names (VAX-31, VAX-24) from risk factor language could indicate strategic pivots or development issues that warrant close monitoring.

Comparing 2026-02-24 vs 2025-02-25View on EDGAR →
FINANCIAL ANALYSIS

PCVX's financials show a company in heavy investment mode with concerning cash dynamics - R&D expenses exploded 67% to $794M while cash reserves dropped 55% to just $174M. Operating losses deepened significantly to -$924M with operating cash outflows worsening 45% to -$656M, while total liabilities increased 54% and stockholders' equity declined 19%. The combination of accelerating cash burn and diminishing cash reserves suggests potential near-term financing needs that could dilute shareholders or constrain operations.

FINANCIAL STATEMENT CHANGES
R&D Expense
P&L
+66.6%
$476.6M→$794.3M

R&D investment increased 66.6% — signals commitment to future product development, though near-term margin impact.

Net Income
P&L
-65.2%
-$463.9M→-$766.6M

Net income declined 65.2% — review whether driven by operations, interest costs, or non-recurring items.

Operating Income
P&L
-62.2%
-$569.5M→-$923.7M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Cash & Equivalents
Balance Sheet
-55.2%
$387.9M→$174.0M

Cash declined 55.2% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Total Liabilities
Balance Sheet
+54.4%
$205.5M→$317.2M

Liabilities grew 54.4% — significant increase in debt or obligations, assess impact on financial flexibility.

Current Liabilities
Balance Sheet
+46.8%
$140.2M→$205.8M

Current liabilities surged 46.8% — significant near-term obligations; verify ability to meet short-term debt.

Operating Cash Flow
Cash Flow
-44.8%
-$452.6M→-$655.6M

Operating cash flow fell 44.8% — earnings quality concerns; investigate working capital changes and non-cash items.

Capital Expenditure
Cash Flow
-38.9%
$22.4M→$13.7M

Capex reduced 38.9% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Stockholders Equity
Balance Sheet
-18.8%
$3.3B→$2.7B

Equity decreased 18.8% — buybacks or losses reducing book value, monitor solvency ratios.

Total Assets
Balance Sheet
-14.5%
$3.5B→$3.0B

Total assets contracted 14.5% — asset sales, write-downs, or balance sheet optimization underway.

LANGUAGE CHANGES
NEW — 2026-02-24
PRIOR — 2025-02-25
ADDED
Form 10-K Summary 159 Signatures 163 All references in this Annual Report on Form 10-K to we, us, our, the Company and Vaxcyte refer to Vaxcyte, Inc.
Our business is highly dependent on the success of our pneumococcal conjugate vaccine ("PCV") candidates.
If we are unable to successfully develop, obtain approval for and effectively commercialize our PCV candidates, our business would be significantly harmed.
We currently rely on third-party manufacturing and supply partners to supply raw materials and components for, and the manufacture of, our preclinical and clinical supplies as well as our vaccine candidates.
The development, review and approval of our product candidates are subject to the operational capacity, processes and resource levels of regulatory authorities, which may fluctuate over time and could delay or adversely affect our business.
We are re-engineering the way highly complex vaccines are made through the XpressCF cell-free protein synthesis platform.
Unlike conventional cell-based approaches, our system for producing difficult-to-make proteins and antigens is intended to develop and deliver high-fidelity vaccines with enhanced immunological benefits that are beyond the capabilities of conventional approaches.
Routine pediatric vaccinations in the United States are estimated to prevent approximately 17 million cases of disease over the lifetimes of each annual birth cohort, and it is estimated that every $1 spent on childhood vaccination results in savings of approximately $11.
Adult vaccination has increased with the introduction of new vaccines along with expanded age recommendations and growing international adoption, which is contributing to the growth of the overall vaccine market.
Our broad-spectrum, carrier-sparing PCV candidates, VAX-31, VAX-24 and VAX-XL, are designed to improve upon standard-of-care PCVs for both adults and children by covering the serotypes that are responsible for increasing portions of IPD in circulation and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains that are currently contained through continued vaccination.
REMOVED
Form 10-K Summary 150 Signatures 154 All references in this Annual Report on Form 10-K to we, us, our, the Company and Vaxcyte refer to Vaxcyte, Inc.
administration in 2025 or executive orders; the pricing, coverage and reimbursement of our vaccine candidates, if approved; our ability and the ability of our third-party contract manufacturers to operate and continue operations; our ability to hire and retain key personnel; our ability to obtain additional financing; and the volatility of the trading price of our common stock.
Our business is highly dependent on the success of our pneumococcal conjugate vaccine candidates, VAX-31 and VAX-24, both of which are in clinical development.
If we are unable to successfully develop, obtain approval for and effectively commercialize VAX-31 or VAX-24, our business would be significantly harmed.
We currently rely on third-party manufacturing and supply partners, including Lonza Ltd.
and Sutro Biopharma, Inc., to supply raw materials and components for, and the manufacture of, our preclinical and clinical supplies as well as our vaccine candidates.
Changes in funding for the FDA and other government agencies could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new products and services from being developed or commercialized in a timely manner, which could negatively impact our business.
We are developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
We are re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc.
Unlike conventional cell-based approaches, our system for producing difficult-to-make proteins and antigens is intended to accelerate our ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →